{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:18:32Z","timestamp":1788257912762,"version":"build-2803163510"},"reference-count":135,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int. J. Mol. Sci.","IJMS"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD), has become one of the most common chronic liver diseases worldwide, representing a major global health challenge closely linked to metabolic syndrome, obesity, and type 2 diabetes mellitus (TD2M). The condition is characterized by a multisystem nature driven by complex multifactorial mechanisms, including insulin resistance, lipotoxicity, mitochondrial dysfunction, genetic predispositions, and gut-liver axis alterations. Although liver biopsy remains the gold standard, non-invasive markers and advanced imaging methods are of key importance for early risk stratification. Furthermore, while liver-related complications such as fibrosis, cirrhosis, and hepatocellular carcinoma (HCC) are significant, cardiovascular disease remains the leading cause of mortality in patients with MASLD. Current management relies primarily on lifestyle modifications, targeted pharmacotherapy (such as pioglitazone, GLP-1 receptor agonists, SGLT-2 inhibitors), and novel experimental therapies. Consequently, MASLD requires a multidisciplinary approach emphasizing early diagnosis, risk stratification, and comprehensive treatment of both hepatic and extrahepatic manifestations.<\/jats:p>","DOI":"10.3390\/ijms27177825","type":"journal-article","created":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:48:36Z","timestamp":1788256116000},"page":"7825","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["From Molecular Mechanisms to Clinical Strategies: A Comprehensive Overview of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-8915-824X","authenticated-orcid":false,"given":"Damian","family":"\u015awierczek","sequence":"first","affiliation":[{"name":"Department of Histology and Cell Pathology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Dreger","sequence":"additional","affiliation":[{"name":"Department of Histology and Cell Pathology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakub","family":"Jatkowski","sequence":"additional","affiliation":[{"name":"Department of Histology and Cell Pathology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6882-1901","authenticated-orcid":false,"given":"Jakub","family":"Kancerek","sequence":"additional","affiliation":[{"name":"Department of Histology and Cell Pathology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bogna","family":"Drozdzowska","sequence":"additional","affiliation":[{"name":"Department and Pathomorphology Division, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6385-2345","authenticated-orcid":false,"given":"Romuald","family":"Wojnicz","sequence":"additional","affiliation":[{"name":"Department of Histology and Cell Pathology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice, 40-055 Katowice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,1]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S2468-1253(26)00011-7","article-title":"Global burden of metabolic dysfunction-associated steatotic liver disease, 1990\u20132023, and projections to 2050: A systematic analysis for the Global Burden of Disease Study 2023","volume":"11","author":"Kim","year":"2026","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4254\/wjh.v16.i1.33","article-title":"Metabolic disease and the liver: A review","volume":"16","author":"Vargas","year":"2024","journal-title":"World J. Hepatol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"110080","DOI":"10.4254\/wjh.v17.i11.110080","article-title":"Non-invasive blood biomarkers for assessment of liver fibrosis in metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Zhao","year":"2025","journal-title":"World J. Hepatol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver, European Association for the Study of Diabetes, and European Association for the Study of Obesity (2016). EASL\u2013EASD\u2013EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J. Hepatol., 64, 1388\u20131402.","DOI":"10.1016\/j.jhep.2015.11.004"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_8","unstructured":"European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), and European Association for the Study of Obesity (EASO) (2024). EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J. Hepatol., 81, 492\u2013542."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1111\/joim.13531","article-title":"Current treatment of non-alcoholic fatty liver disease","volume":"292","author":"Paternostro","year":"2022","journal-title":"J. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): A systematic review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1161\/CIRCULATIONAHA.124.070535","article-title":"Cardiovascular-Liver-Metabolic Health: Recommendations in Screening, Diagnosis, and Management of Metabolic Dysfunction-Associated Steatotic Liver Disease in Cardiovascular Disease via Modified Delphi Approach","volume":"151","author":"Chew","year":"2024","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1016\/j.cgh.2020.12.022","article-title":"Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study","volume":"19","author":"Lee","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Fu, T., Ling, J., Zhao, H., Lin, K., Deng, Y., Zhang, M., Qi, X., Yu, P., Lin, W., and Liu, X. (2025). Comparative association between NAFLD and MAFLD with cardiovascular events and mortality: Evidence from observational studies. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0312650"},{"key":"ref_15","first-page":"e91628","article-title":"Clinical Predictors of Progression from Metabolic Dysfunction-Associated Steatotic Liver Disease to Cirrhosis: A Narrative Review","volume":"17","author":"Abucha","year":"2025","journal-title":"Cureus"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e16106","DOI":"10.1111\/liv.16106","article-title":"PNPLA3 I148M Interacts with Environmental Triggers to Cause Human Disease","volume":"45","author":"Speliotes","year":"2025","journal-title":"Liver Int."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100835","DOI":"10.1016\/j.jhepr.2023.100835","article-title":"Non-alcoholic fatty liver disease in women\u2014Current knowledge and emerging concepts","volume":"5","author":"Eng","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Weiskirchen, R., and Lonardo, A. (2025). Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26199594"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.cgh.2019.12.026","article-title":"Nonalcoholic Fatty Liver Disease and Fibrosis Associated with Increased Risk of Cardiovascular Events in a Prospective Study","volume":"18","author":"Baratta","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101101","DOI":"10.1016\/j.aohep.2023.101101","article-title":"Hepatocellular carcinoma screening in NAFLD: The paradox of nearly half the cases arising in non-cirrhotic low risk patients","volume":"28","author":"Machado","year":"2023","journal-title":"Ann. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1097\/MEG.0000000000001419","article-title":"Hepatocellular carcinoma in the noncirrhotic liver: A literature review","volume":"31","author":"Zhang","year":"2019","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"329","DOI":"10.14218\/JCTH.2021.00178","article-title":"Metabolic-associated Fatty Liver Disease (MAFLD): A Multi-systemic Disease Beyond the Liver","volume":"10","author":"Kaya","year":"2021","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra2412865","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"393","author":"Targher","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: A tale of two \"hits\"?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/hep.24001","article-title":"Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis","volume":"52","author":"Tilg","year":"2010","journal-title":"Hepatology"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3920196","DOI":"10.1155\/2020\/3920196","article-title":"The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD)","volume":"2020","author":"Tanase","year":"2020","journal-title":"J. Diabetes Res."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Sakurai, Y., Kubota, N., Yamauchi, T., and Kadowaki, T. (2021). Role of Insulin Resistance in MAFLD. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22084156"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/ijms21113863","article-title":"The Role of Insulin Resistance and Diabetes in Nonalcoholic Fatty Liver Disease","volume":"21","author":"Fujii","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.2337\/diabetes.51.10.2929","article-title":"Tumor necrosis factor-alpha stimulates lipolysis in differentiated human adipocytes through activation of extracellular signal-related kinase and elevation of intracellular cAMP","volume":"51","author":"Zhang","year":"2002","journal-title":"Diabetes"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1126\/science.1160794","article-title":"A stress signaling pathway in adipose tissue regulates hepatic insulin resistance","volume":"322","author":"Sabio","year":"2008","journal-title":"Science"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"9547613","DOI":"10.1155\/2018\/9547613","article-title":"Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease","volume":"2018","author":"Masarone","year":"2018","journal-title":"Oxidative Med. Cell. Longev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/s42255-019-0044-9","article-title":"Liver macrophages regulate systemic metabolism through non-inflammatory factors","volume":"1","author":"Morgantini","year":"2019","journal-title":"Nat. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e9302","DOI":"10.15252\/emmm.201809302","article-title":"The role of the microbiome in NAFLD and NASH","volume":"11","author":"Kolodziejczyk","year":"2019","journal-title":"EMBO Mol. Med."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1007\/s00018-019-03011-w","article-title":"The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD)","volume":"76","author":"Safari","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"12511","DOI":"10.1073\/pnas.0601056103","article-title":"Metabolic profiling reveals a contribution of gut microbiota to fatty liver phenotype in insulin-resistant mice","volume":"103","author":"Dumas","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_36","first-page":"115","article-title":"Serum biomarkers for liver fibrosis assessment","volume":"5","year":"2023","journal-title":"Adv. Lab. Med."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Zou, H., Pan, W., and Sun, X. (2025). Assessment of the diagnostic efficacy of five non-invasive tests for MASLD: External validation utilizing data from two cohorts. Front. Nutr., 12.","DOI":"10.3389\/fnut.2025.1571487"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1665-2681(19)31836-8","article-title":"AST to platelet ratio index (APRI) for the noninvasive evaluation of liver fibrosis","volume":"7","year":"2008","journal-title":"Ann. Hepatol."},{"key":"ref_39","first-page":"103","article-title":"Noninvasive assessment of liver fibrosis with the aspartate transaminase to platelet ratio index (APRI): Usefulness in patients with chronic liver disease: APRI in chronic liver disease","volume":"11","author":"Yilmaz","year":"2011","journal-title":"Hepat. Mon."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1055\/s-0038-1676805","article-title":"Child-Pugh Classification: Time to Abandon?","volume":"39","author":"Kok","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2877","DOI":"10.1097\/MD.0000000000002877","article-title":"Child-Pugh Versus MELD Score for the Assessment of Prognosis in Liver Cirrhosis: A Systematic Review and Meta-Analysis of Observational Studies","volume":"95","author":"Peng","year":"2016","journal-title":"Medicine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1002\/bjs.1800600817","article-title":"Transection of the oesophagus for bleeding oesophageal varices","volume":"60","author":"Pugh","year":"1973","journal-title":"Br. J. Surg."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1055\/s-0039-1688750","article-title":"A Critical Review of MELD as a Reliable Tool for Transplant Prioritization","volume":"39","author":"Sacleux","year":"2019","journal-title":"Semin. Liver Dis."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive Assessment of Liver Disease in Patients with Nonalcoholic Fatty Liver Disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"189","DOI":"10.14366\/usg.24219","article-title":"The new definition of metabolic dysfunction-associated steatotic liver disease: The role of ultrasound and elastography","volume":"44","author":"Jin","year":"2025","journal-title":"Ultrasonography"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/1744666X.2023.2294046","article-title":"The pathophysiology of MASLD: An immunometabolic perspective","volume":"20","author":"Grabherr","year":"2024","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1111\/liv.12840","article-title":"Clinical value of liver ultrasound for the diagnosis of nonalcoholic fatty liver disease in overweight and obese patients","volume":"35","author":"Bril","year":"2015","journal-title":"Liver Int."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00261-022-03482-9","article-title":"Detection of fatty liver using virtual non-contrast dual-energy CT","volume":"47","author":"Zhang","year":"2022","journal-title":"Abdom. Radiol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1053\/j.sult.2016.08.003","article-title":"Hepatic Steatosis: Etiology, Patterns, and Quantification","volume":"37","author":"Idilman","year":"2016","journal-title":"Semin. Ultrasound CT MR"},{"key":"ref_50","first-page":"561CT","article-title":"Dual-Energy CT Principles and Applications","volume":"91","author":"Chellini","year":"2020","journal-title":"Radiol. Technol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/S2468-1253(19)30383-8","article-title":"FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study","volume":"5","author":"Newsome","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/jama.2024.1447","article-title":"Vibration-Controlled Transient Elastography Scores to Predict Liver-Related Events in Steatotic Liver Disease","volume":"331","author":"Lin","year":"2024","journal-title":"JAMA"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Dawod, S., and Brown, K. (2024). Non-invasive testing in metabolic dysfunction-associated steatotic liver disease. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1499013"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Kang, Y.W., Baek, Y.H., Lee, J.H., Roh, Y.H., Kwon, H.J., Moon, S.Y., Son, M.K., and Jeong, J.S. (2024). Assessing the Utility of Acoustic Radiation Force Impulse in the Evaluation of Non-Alcoholic Fatty Liver Disease with Severe Obesity or Steatosis. Diagnostics, 14.","DOI":"10.3390\/diagnostics14111083"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1002\/jmri.27292","article-title":"Multiparametric MRI in Patients with Nonalcoholic Fatty Liver Disease","volume":"53","author":"Schaapman","year":"2021","journal-title":"J. Magn. Reson. Imaging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1016\/j.cgh.2020.08.061","article-title":"Change in MRI-PDFF and Histologic Response in Patients with Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis","volume":"19","author":"Stine","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","article-title":"Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD","volume":"18","author":"Tamaki","year":"2022","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"e231007","DOI":"10.1148\/radiol.231007","article-title":"Association between Liver MRI Proton Density Fat Fraction and Liver Disease Risk","volume":"309","author":"Xia","year":"2023","journal-title":"Radiology"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"S302","DOI":"10.3350\/cmh.2022.0329","article-title":"Non-alcoholic fatty liver disease: The pathologist\u2019s perspective","volume":"29","author":"Leow","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1016\/j.csbj.2023.03.048","article-title":"Artificial intelligence and deep learning: New tools for histopathological diagnosis of nonalcoholic fatty liver disease\/nonalcoholic steatohepatitis","volume":"21","author":"Takahashi","year":"2023","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_61","unstructured":"Kurtovic, E., and Zubair, M. (2025). Mallory Bodies. StatPearls [Internet], StatPearls Publishing."},{"key":"ref_62","unstructured":"Gurina, T.S., and Simms, L. (2025). Histology, Staining. StatPearls, StatPearls Publishing."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.semdp.2006.11.006","article-title":"Special stains in diagnostic liver pathology","volume":"23","author":"Lefkowitch","year":"2006","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Choi, J.H. (2025). Histological and Molecular Evaluation of Liver Biopsies: A Practical and Updated Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26167729"},{"key":"ref_65","first-page":"14","article-title":"Pathology of non-alcoholic fatty liver disease","volume":"2","author":"Chan","year":"2016","journal-title":"Int. J. Dig. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Liang, H., Zhang, D., Wei, N., Xi, P., Ge, H., and Zhang, Y. (2025). A new perspective on non-invasive diagnosis of non- alcoholic fatty liver disease: Evidence integration of inflammatory and metabolic biomarkers based on a scoping review. Front. Endocrinol., 16.","DOI":"10.3389\/fendo.2025.1652996"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"John, K., Franck, M., Al Aoua, S., Rau, M., Huber, Y., Schattenberg, J.M., Geier, A., Bahr, M.J., Wedemeyer, H., and Schulze-Osthoff, K. (2022). Non-Invasive Detection of Fibrotic NASH in NAFLD Patients with Low or Intermediate FIB-4. J. Clin. Med., 11.","DOI":"10.3390\/jcm11154394"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"124","DOI":"10.20892\/j.issn.2095-3941.2018.0018","article-title":"Progress in non-invasive detection of liver fibrosis","volume":"15","author":"Li","year":"2018","journal-title":"Cancer Biol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.3350\/cmh.2022.0424","article-title":"Non-alcoholic fatty liver disease: Definition and subtypes","volume":"29","author":"Han","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"17562848241276334","DOI":"10.1177\/17562848241276334","article-title":"Modernizing metabolic dysfunction-associated steatotic liver disease diagnostics: The progressive shift from liver biopsy to noninvasive techniques","volume":"17","author":"Hudson","year":"2024","journal-title":"Ther. Adv. Gastroenterol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"E172","DOI":"10.1055\/a-1978-6652","article-title":"EUS-guided left lobe liver biopsy: Safer modality with similar diagnostic yield as right lobe: A pilot study","volume":"11","author":"Sharma","year":"2023","journal-title":"Endosc. Int. Open"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e242349","DOI":"10.1148\/radiol.242349","article-title":"Three-Dimensional Vector MR Elastography for Evaluating Tissue Mechanical Heterogeneity to Assess Liver Disease Progression","volume":"315","author":"Wu","year":"2025","journal-title":"Radiology"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.cgh.2019.12.025","article-title":"High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies from Patients with Nonalcoholic Fatty Liver Disease","volume":"18","author":"Forlano","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Wei, X., Qiu, L., Wang, X., Shao, C., Zhao, J., Yang, Q., Chen, J., Yin, M., Ehman, R.L., and Zhang, J. (2025). The Relationship Between Non-Invasive Tests and Digital Pathology for Quantifying Liver Fibrosis in MASLD. Diagnostics, 15.","DOI":"10.3390\/diagnostics15192475"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00421-018-3818-y","article-title":"Effects of sprint interval training on ectopic lipids and tissue-specific insulin sensitivity in men with non-alcoholic fatty liver disease","volume":"118","author":"Sargeant","year":"2018","journal-title":"Eur. J. Appl. Physiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.2337\/dc10-0856","article-title":"Effect of a 12-Month Intensive Lifestyle Intervention on Hepatic Steatosis in Adults with Type 2 Diabetes","volume":"33","author":"Lazo","year":"2010","journal-title":"Diabetes Care"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jhep.2013.02.012","article-title":"The Mediterranean diet improves hepatic steatosis and insulin sensitivity in individuals with non-alcoholic fatty liver disease","volume":"59","author":"Ryan","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_79","first-page":"1439","article-title":"FDA Okays First Drug for Scarring from Fatty Liver Disease","volume":"331","author":"Harris","year":"2024","journal-title":"JAMA"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.eprac.2024.04.016","article-title":"Role of Resmetirom, a Liver-Directed, Thyroid Hormone Receptor Beta-Selective Agonist, in Managing Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis","volume":"30","author":"Dutta","year":"2024","journal-title":"Endocr. Pract."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e70920","DOI":"10.1002\/hsr2.70920","article-title":"Resmetirom: A Breakthrough in the Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"8","author":"Shakeel","year":"2025","journal-title":"Health Sci. Rep."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of Resmetirom on Noninvasive Endpoints in a 36-Week Phase 2 Active Treatment Extension Study in Patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Stasi, C., and Mega, A. (2025). Improvement of Liver Fibrosis in Patients with MASLD Undergoing Pioglitazone Treatment: An Update. Life, 15.","DOI":"10.3390\/life15111682"},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Lian, J., and Fu, J. (2021). Pioglitazone for NAFLD Patients with Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis. Front. Endocrinol., 12.","DOI":"10.3389\/fendo.2021.615409"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jhep.2024.06.034","article-title":"Should the new EASL\u2013EASD\u2013EASO Clinical Practice Guidelines on MASLD recommend pioglitazone as a MASH-targeted pharmacotherapy?","volume":"82","author":"Sposito","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"100737","DOI":"10.1016\/j.clinsp.2025.100737","article-title":"Long-term pioglitazone use in MASLD patients: Insights from a multicentric preliminary study","volume":"80","author":"Pereira","year":"2025","journal-title":"Clinics"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Nevola, R., Epifani, R., Imbriani, S., Tortorella, G., Aprea, C., Galiero, R., Rinaldi, L., Marfella, R., and Sasso, F.C. (2023). GLP-1 Receptor Agonists in Non-Alcoholic Fatty Liver Disease: Current Evidence and Future Perspectives. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24021703"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2S28","DOI":"10.1016\/S1262-3636(17)30070-8","article-title":"GLP-1 receptor agonists in NAFLD","volume":"43","author":"Petit","year":"2017","journal-title":"Diabetes Metab."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/dme.13697","article-title":"Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: A post hoc analysis of the AWARD programme","volume":"35","author":"Cusi","year":"2018","journal-title":"Diabet. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/hep.23569","article-title":"Glucagon-like peptide-1 receptor is present on human hepatocytes and has a direct role in decreasing hepatic steatosis in vitro by modulating elements of the insulin signaling pathway","volume":"51","author":"Gupta","year":"2010","journal-title":"Hepatology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4947","DOI":"10.1038\/s41598-025-89408-z","article-title":"Glucagon-like peptide-1 receptor agonists improve metabolic dysfunction-associated steatotic liver disease outcomes","volume":"15","author":"Havranek","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1097\/HEP.0000000000001608","article-title":"Semaglutide therapy for metabolic dysfunction-associated steatohepatitis: November 2025 updates to AASLD Practice Guidance","volume":"83","author":"Bansal","year":"2026","journal-title":"Hepatology"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"bqab157","DOI":"10.1210\/endocr\/bqab157","article-title":"SGLT2 Inhibition for Cardiovascular Diseases, Chronic Kidney Disease, and NAFLD","volume":"162","author":"Ala","year":"2021","journal-title":"Endocrinology"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.2337\/db19-0991","article-title":"Empagliflozin ameliorates obesityrelated cardiac dysfunction by regulating Sestrin2-mediated AMPK-mTOR signaling and redox homeostasis in high-fat dietinduced obese mice","volume":"69","author":"Sun","year":"2020","journal-title":"Diabetes"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"e083735","DOI":"10.1136\/bmj-2024-083735","article-title":"Effect of dapagliflozin on metabolic dysfunction-associated steatohepatitis: Multicentre, double blind, randomised, placebo controlled trial","volume":"389","author":"Lin","year":"2025","journal-title":"BMJ"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"101372","DOI":"10.1016\/j.jhepr.2025.101372","article-title":"Statins in MASLD: Challenges and future directions","volume":"7","author":"Zhou","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Milaciu, M.V., Vesa, \u0218.C., Boc\u0219an, I.C., Cium\u0103rnean, L., S\u00e2mpelean, D., Negrean, V., Pop, R.M., Matei, D.M., Pa\u0219ca, S., and R\u0103chi\u0219an, A.L. (2019). Paraoxonase-1 Serum Concentration and PON1 Gene Polymorphisms: Relationship with Non-Alcoholic Fatty Liver Disease. J. Clin. Med., 8.","DOI":"10.3390\/jcm8122200"},{"key":"ref_100","first-page":"e104139","article-title":"Statin Therapy and Clinical Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis","volume":"18","author":"Gillani","year":"2026","journal-title":"Cureus"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Prasoppokakorn, T. (2025). Applicability of Statins in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Livers, 5.","DOI":"10.3390\/livers5010004"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.3892\/ijmm.2016.2766","article-title":"Rosuvastatin as a potential preventive drug for the development of hepatocellular carcinoma associated with non-alcoholic fatty liver disease in mice","volume":"38","author":"Yokohama","year":"2016","journal-title":"Int. J. Mol. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.cgh.2022.01.057","article-title":"Statin Use and Reduced Hepatocellular Carcinoma Risk in Patients with Nonalcoholic Fatty Liver Disease","volume":"21","author":"Zou","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Chen, H., Huang, M., Zhang, D., Wang, H., Wang, D., Li, M., Wang, X., Zhu, R., Liu, J., and Ma, L. (2024). Metformin\u2019s effect on metabolic dysfunction-associated steatotic liver disease through the miR-200a-5p and AMPK\/SERCA2b pathway. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1477212"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1136\/flgastro-2024-102856","article-title":"Role of anti-diabetic medications in the management of MASLD","volume":"16","author":"Isaacs","year":"2025","journal-title":"Frontline Gastroenterol."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Lin, C.-L., Li, W.-Y., Wu, S.-J., Chen, P.M.T., Chen, A.Y., Fann, C.S., and Chen, Y.-A. (2026). The Usefulness of Metformin and Ganwei for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Randomized, Placebo-Controlled Trial. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27052411"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s00109-025-02551-y","article-title":"Patient-specific effects of metformin on the hepatic metabolism in adolescents with metabolic dysfunction-associated steatotic liver disease (MASLD)","volume":"103","author":"Hudert","year":"2025","journal-title":"J. Mol. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/j.jhep.2016.07.033","article-title":"NAFLD and liver transplantation: Current burden and expected challenges","volume":"65","author":"Pais","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"572637","DOI":"10.2147\/JIR.S572637","article-title":"The Role of Galectin-3 in Liver Inflammation and Fibrosis","volume":"19","author":"Lurje","year":"2026","journal-title":"J. Inflamm. Res."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Chalasani, N., Vuppalanchi, R., Noureddin, M., Shiffman, M.L., Lawitz, E., Mena, E., Gunn, N.T., de Guevara, L.L., Elgouhari, H., and Safadi, R. (2026). Efficacy and safety of belapectin for the prevention of esophageal varices in patients with MASH cirrhosis: The randomized, placebo-controlled NAVIGATE trial. Hepatology, ahead of print.","DOI":"10.1097\/HEP.0000000000001774"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Comeglio, P., Guarnieri, G., Filippi, S., Cellai, I., Acciai, G., Holyer, I., Zetterberg, F., Leffler, H., Kahl-Knutson, B., and Sarchielli, E. (2024). The galectin-3 inhibitor selvigaltin reduces liver inflammation and fibrosis in a high fat diet rabbit model of metabolic-associated steatohepatitis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1430109"},{"key":"ref_112","doi-asserted-by":"crossref","unstructured":"Cui, X., Sun, Q., and Wang, H. (2025). Targeting fibroblast growth factor (FGF)-21: A promising strategy for metabolic dysfunction-associated steatotic liver disease treatment. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1510322"},{"key":"ref_113","doi-asserted-by":"crossref","unstructured":"Prikhodko, V.A., and Okovityi, S.V. (2026). Current Drug Development Pipeline for MASLD and MASH: Focusing on Cardiovascular Comorbidities. Biomedicines, 14.","DOI":"10.3390\/biomedicines14040909"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0140-6736(25)01073-6","article-title":"Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial","volume":"406","author":"Noureddin","year":"2025","journal-title":"Lancet"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"3309","DOI":"10.1111\/dom.16348","article-title":"Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction-associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta-analysis","volume":"27","author":"Zhong","year":"2025","journal-title":"Diabetes Obes. Metab."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"100590","DOI":"10.37349\/edd.2025.100590","article-title":"PPARs in molecular pathogenesis and drug treatment of type 2 diabetes-related MASLD","volume":"4","author":"Lonardo","year":"2025","journal-title":"Explor. Dig. Dis."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1186\/s13578-024-01267-9","article-title":"New Advances in Drug Development for Metabolic Dysfunction-Associated Diseases and Alcohol-Associated Liver Disease","volume":"14","author":"Zhang","year":"2024","journal-title":"Cell Biosci."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"e70144","DOI":"10.1002\/edm2.70144","article-title":"Effectiveness of Saroglitazar in MASLD Patients: A Prospective, Real-World Assessment of Liver and Metabolic Health","volume":"9","author":"Gupta","year":"2026","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1097\/MPG.0000000000003796","article-title":"An Open Label, Randomized, Multicenter Study of Elafibranor in Children with Nonalcoholic Steatohepatitis","volume":"77","author":"Goyal","year":"2023","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1056\/NEJMoa2210645","article-title":"Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk","volume":"387","author":"Glynn","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"178088","DOI":"10.1016\/j.ejphar.2025.178088","article-title":"Evaluating causal protective effect of dual GLP-1R\/GIPR agonists on MASLD: A Mendelian randomization and colocalization study","volume":"1005","author":"Cai","year":"2025","journal-title":"Eur. J. Pharmacol."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1056\/NEJMoa2401943","article-title":"Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis","volume":"391","author":"Loomba","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Abenavoli, L., Loricchio, A.G., Lopez, I., Morano, D., Ismaiel, A., Dumitrascu, D.L., and Luzza, F. (2026). Metabolic Dysfunction-Associated Steatotic Liver Disease and Incretin Receptor Agonists: A Metabolic Approach to Halting Liver Disease Progression. Medicina, 62.","DOI":"10.3390\/medicina62050986"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa2401755","article-title":"A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis","volume":"391","author":"Sanyal","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jhep.2024.07.006","article-title":"Effect of pemvidutide, a GLP-1\/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study","volume":"82","author":"Harrison","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1038\/s41591-024-03018-2","article-title":"Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: A randomized phase 2a trial","volume":"30","author":"Sanyal","year":"2024","journal-title":"Nat. Med."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.gastha.2023.09.013","article-title":"Farnesoid X Receptor Agonists: A Promising Therapeutic Strategy for Gastrointestinal Diseases","volume":"3","author":"Almeqdadi","year":"2023","journal-title":"Gastro Hep Adv."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.jhep.2022.10.023","article-title":"Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH","volume":"78","author":"Ratziu","year":"2023","journal-title":"J. Hepatol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: Interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"ref_131","doi-asserted-by":"crossref","unstructured":"Liu, J., and Wu, X. (2026). Obeticholic acid as an index farnesoid X receptor scaffold in metabolic dysfunction-associated steatohepatitis: A testable model for efficacy-liability separation and biomarker interpretation. Front. Pharmacol., 17.","DOI":"10.3389\/fphar.2026.1879097"},{"key":"ref_132","first-page":"74472","article-title":"A precision-constrained framework for evaluating noninvasive biomarkers in MASLD and beyond","volume":"17","author":"Zhang","year":"2026","journal-title":"Nat. Commun."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/gutjnl-2025-335598","article-title":"Thrombospondin-2 is a performant biomarker of at-risk MASH and advanced MASH fibrosis in a large multicentre European cohort","volume":"75","author":"Ratziu","year":"2026","journal-title":"Gut"},{"key":"ref_134","doi-asserted-by":"crossref","unstructured":"Arshad, F., Chinnappan, R., Broering, D.C., Raptis, D.A., Mir, T.A., Khan, M.I., and Yaqinuddin, A. (2026). Clinical biomarkers and biosensors for early detection of metabolic dysfunction-associated steatohepatitis (MASH): A translational perspective. Front. Bioeng. Biotechnol., 14.","DOI":"10.3389\/fbioe.2026.1748835"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.1111\/dom.70326","article-title":"Non-invasive diagnosis of metabolic dysfunction-associated steatotic liver disease: Current status, challenges, and future directions","volume":"28","author":"Ma","year":"2026","journal-title":"Diabetes Obes. Metab."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7825\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T09:58:23Z","timestamp":1788256703000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/17\/7825"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,1]]},"references-count":135,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["ijms27177825"],"URL":"https:\/\/doi.org\/10.3390\/ijms27177825","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,1]]}}}